Omeprazole indications

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

List of indications

Duodenal ulcer

• H. pylori infection and duodenal ulcer disease

Gastric ulcer

Gastroesophageal reflux disease

• Symptomatic GERD
• Erosive esophagitis
• Maintenance of healing of erosive esophagitis
• Pathological hypersecretory conditions

---

Duodenal ulcer

Omeprazole Delayed-Release Capsules are indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. Return to top

H. pylori infection and duodenal ulcer disease

Omeprazole Delayed-Release Capsules, in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori.
Omeprazole Delayed-Release Capsules, in combination with clarithromycin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori.
Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Among patients who fail therapy, Omeprazole with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted. Return to top

Gastric ulcer

Omeprazole Delayed-Release Capsules are indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. Return to top

Gastroesophageal reflux disease

Symptomatic GERD

Omeprazole Delayed-Release Capsules are indicated for the treatment of heartburn and other symptoms associated with GERD. Return to top

Erosive esophagitis

Omeprazole Delayed-Release Capsules are indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy.
The efficacy of Omeprazole used for longer than 8 weeks in these patients has not been established. In the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. If there is recurrence of erosive esophagitis or GERD symptoms (e.g., heartburn), additional 4-8 week courses of Omeprazole may be considered. Return to top

Maintenance of healing of erosive esophagitis

Omeprazole Delayed-Release Capsules are indicated to maintain healing of erosive esophagitis. Controlled studies do not extend beyond 12 months. Return to top

Pathological hypersecretory conditions

Omeprazole Delayed-Release Capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis). Return to top

---

The content of this page is taken from the FDA package insert for this drug and should not be edited.